Vincent Rajkumar, MD, from the Mayo Clinic, Rochester, MN speaks about the importance of the numerous different types of funding that are available for clinical trials for multiple myeloma (MM) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Current clinical trials can be funded by several different types of entities and it is important to know how they can affect the pace and objectives of the clinical trial itself. Company funded trials tend to have short-term goals and can be influenced by the philosophy of the company. On the other hand, government funded trials can take longer than necessary to complete due to inadequate funding, meaning the results can be outdated at the time of release. Dr Rajkumar highlights that clinical trials require new sources of funding that allow them to focus and provide results for big strategic questions that can cure disease.